Search

Your search keyword '"Filippatos, Gerasimos"' showing total 530 results

Search Constraints

Start Over You searched for: Author "Filippatos, Gerasimos" Remove constraint Author: "Filippatos, Gerasimos"
530 results on '"Filippatos, Gerasimos"'

Search Results

151. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology.

152. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial.

153. Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial.

154. Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC).

155. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial.

156. Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.

157. Heart failure with normal LVEF in BIOSTAT-CHF.

158. Noninvasive ventilation improved dyspnea but did not reduce short-term mortality in acute cardiogenic pulmonary edema.

159. Cachexia: Common, Deadly, With an Urgent Need for Precise Definition and New Therapies

160. Introduction

161. Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment

162. Management with a pulmonary artery catheter did not reduce all-cause mortality in critically ill patients: COMMENTARY.

164. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?

165. Distinct pathophysiological pathways in women and men with heart failure.

166. Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy - A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology.

167. Endothelial glycocalyx integrity in oncological patients.

168. Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology.

169. Pathophysiological pathways in patients with heart failure and atrial fibrillation.

171. Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure.

172. Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT‐HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure).

173. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.

174. Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF.

175. Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.

176. Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.

177. Decongestion, kidney injury and prognosis in patients with acute heart failure.

178. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry.

179. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced.

180. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.

181. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).

182. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies ( SOCRATES).

183. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.

184. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

185. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction.

186. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.

187. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

188. Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology.

189. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Registry.

190. Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.

191. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.

192. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial.

193. Insights Into Onco-Cardiology: Atrial Fibrillation in Cancer.

194. Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups.

195. Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups.

196. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)

197. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot).

198. Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF.

199. Front Cover.

200. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology.

Catalog

Books, media, physical & digital resources